Cargando…

Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors

Oraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P‐glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers that would otherwise be treated with intravenous paclitaxel. He...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Jimmy, Jackson, Christopher G. C. A., Deva, Sanjeev, Hung, Tak, Clarke, Katriona, Segelov, Eva, Chao, Tsu‐Yi, Dai, Ming‐Shen, Yeh, Hsien‐Tang, Ma, Wen Wee, Kramer, Douglas, Chan, Wing‐Kai, Kwan, Rudolf, Cutler, David, Zhi, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286714/ https://www.ncbi.nlm.nih.gov/pubmed/35470967 http://dx.doi.org/10.1002/psp4.12799

Ejemplares similares

Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study
por: Dai, Ming-Shen, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel
por: Chen, Nianhang, et al.
Publicado: (2014)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics
por: Lee, Jaeok, et al.
Publicado: (2019)

Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
por: van Doorn, Leni, et al.
Publicado: (2021)

Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
por: Rugo, Hope S., et al.
Publicado: (2023)

Pharmacokinetic Alteration of Paclitaxel by Ferulic Acid Derivative
por: Lee, Jaeok, et al.
Publicado: (2019)

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
por: Bozionelou, V, et al.
Publicado: (2007)

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
por: Borgå, Olof, et al.
Publicado: (2019)

Effects of Adamantyl Derivatives on Pharmacokinetic Behavior of Paclitaxel in Rats
por: Kim, Kyung Mi, et al.
Publicado: (2017)

2043: Pharmacokinetic prediction of paclitaxel-induced peripheral neuropathy
por: Hertz, Daniel L., et al.
Publicado: (2018)

Clinical trials and progress with paclitaxel in ovarian cancer
por: Kumar, Sanjeev, et al.
Publicado: (2010)

Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
por: Wang, Yonglu, et al.
Publicado: (2011)

Pharmacokinetics and biodistribution of negatively charged pectin nanoparticles encapsulating paclitaxel
por: Verma, Anita K., et al.
Publicado: (2013)

Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
por: Yamada, Kazuhiko, et al.
Publicado: (2010)

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
por: Lassen, U, et al.
Publicado: (2010)

Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors
por: Chow, Laura Q. M., et al.
Publicado: (2016)

Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients
por: Borgå, Olof, et al.
Publicado: (2019)

Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients
por: So, W. Venus, et al.
Publicado: (2018)

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
por: Tellingen, O van, et al.
Publicado: (1999)

Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.
por: Webster, L. K., et al.
Publicado: (1996)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

Breast milk paclitaxel excretion following intravenous chemotherapy—a case report
por: Jackson, Christopher G. C. A., et al.
Publicado: (2019)

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment
por: Heijns, Joan B., et al.
Publicado: (2008)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.
por: Chao, Y., et al.
Publicado: (1998)

Pharmacokinetic Evaluation of Paclitaxel in South Indian Cancer Patients: A Prospective Study
por: Vasantha, J, et al.
Publicado: (2011)

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
por: Li, Qingmei, et al.
Publicado: (2018)

Predicting Paclitaxel Disposition in Humans With Whole‐Body Physiologically‐Based Pharmacokinetic Modeling
por: Fu, Qiang, et al.
Publicado: (2019)

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
por: Steins, Anne, et al.
Publicado: (2017)

Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer
por: Gota, Vikram, et al.
Publicado: (2021)

Albumin-bound paclitaxel in solid tumors: clinical development and future directions
por: Kundranda, Madappa N, et al.
Publicado: (2015)

nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
por: Soliman, Hatem H
Publicado: (2016)

Phase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers
por: Kunos, Charles A., et al.
Publicado: (2017)

Combined Delivery of Paclitaxel and Tanespimycin via Micellar Nanocarriers: Pharmacokinetics, Efficacy and Metabolomic Analysis
por: Katragadda, Usha, et al.
Publicado: (2013)

Pharmacokinetic profile of paclitaxel in the plasma, lung, and diaphragm following intravenous or intrapleural administration in rats
por: Li, Jie, et al.
Publicado: (2015)

Effects of Jia-Wei-Xiao-Yao-San on the Peripheral and Lymphatic Pharmacokinetics of Paclitaxel in Rats
por: Hou, Mei-Ling, et al.
Publicado: (2016)

Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac(®)) in a Rodent Model
por: Verco, James, et al.
Publicado: (2019)

Pharmacokinetics and tissue distribution of PGG–paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts
por: Wang, Xinghe, et al.
Publicado: (2009)

A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors
por: Cohen, Adam L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a4fmjmbl18cb5rj77q1f81csa7